Brokerages Set Assembly Biosciences, Inc. (NASDAQ:ASMB) Target Price at $44.00

Assembly Biosciences, Inc. (NASDAQ:ASMB) has been assigned an average rating of “Moderate Buy” from the six analysts that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $44.00.

A number of analysts recently issued reports on ASMB shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Assembly Biosciences in a research report on Friday, July 17th. Mizuho set a $45.00 price target on shares of Assembly Biosciences and gave the company an “outperform” rating in a research report on Monday, June 15th. Guggenheim reiterated a “buy” rating and set a $43.00 price objective on shares of Assembly Biosciences in a research note on Thursday, May 28th. Wall Street Zen lowered shares of Assembly Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 16th. Finally, HC Wainwright restated a “buy” rating and set a $50.00 target price on shares of Assembly Biosciences in a report on Tuesday.

Assembly Biosciences News Roundup

Here are the key news stories impacting Assembly Biosciences this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS forecast to $2.28 from $1.90 and maintained a “Buy” rating with a $50 price target, signaling improved expectations for the company’s near-term earnings. HC Wainwright Assembly Biosciences estimates
• Positive Sentiment: The analyst also raised estimates for several periods, including Q3 2026 EPS to a loss of $0.44 from a loss of $0.69, Q1 2027 EPS to positive $0.02 from a loss of $0.16, and FY2027 EPS to a loss of $0.02 from a loss of $0.77. These revisions suggest expectations for a substantially better earnings trajectory.
• Positive Sentiment: Assembly Biosciences was added to Zacks’ Rank #1 (Strong Buy) list and its momentum-focused Strong Buy list. Such rankings may attract momentum-oriented investors, although they are based largely on quantitative factors. Zacks momentum stocks
• Positive Sentiment: Analysts continue to show constructive sentiment: HC Wainwright reiterated its “Buy” rating, while the broader analyst consensus was reported as “Moderate Buy.” Another Zacks analysis cited average analyst price targets implying significant potential upside, while cautioning that price targets are an imperfect forecasting tool. HC Wainwright Buy rating
• Negative Sentiment: HC Wainwright reduced its Q4 2026 EPS forecast to $3.19 from $3.69, partially offsetting the broader upward revisions. The company remains dependent on future earnings improvements, and analyst forecasts for some 2027 quarters still call for losses.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. RA Capital Management L.P. purchased a new stake in shares of Assembly Biosciences in the third quarter worth about $26,122,000. Janus Henderson Group PLC raised its holdings in shares of Assembly Biosciences by 1.4% during the 1st quarter. Janus Henderson Group PLC now owns 849,309 shares of the biopharmaceutical company’s stock valued at $23,479,000 after buying an additional 11,384 shares during the period. Paradigm Biocapital Advisors LP purchased a new stake in shares of Assembly Biosciences during the 4th quarter valued at about $22,625,000. Vanguard Group Inc. lifted its position in Assembly Biosciences by 97.8% during the 3rd quarter. Vanguard Group Inc. now owns 502,112 shares of the biopharmaceutical company’s stock worth $12,854,000 after acquiring an additional 248,287 shares in the last quarter. Finally, Parkman Healthcare Partners LLC acquired a new position in Assembly Biosciences during the 3rd quarter worth approximately $6,425,000. Institutional investors and hedge funds own 19.92% of the company’s stock.

Assembly Biosciences Trading Up 2.5%

ASMB stock opened at $34.38 on Friday. The stock has a 50-day moving average price of $27.11 and a two-hundred day moving average price of $27.60. Assembly Biosciences has a 12-month low of $20.23 and a 12-month high of $39.71. The company has a market cap of $700.01 million, a PE ratio of 33.71 and a beta of 1.10.

Assembly Biosciences (NASDAQ:ASMB) last released its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.52. The company had revenue of $13.37 million for the quarter, compared to the consensus estimate of $8.60 million. Assembly Biosciences had a negative return on equity of 0.02% and a negative net margin of 0.06%. Equities analysts forecast that Assembly Biosciences will post 2.28 EPS for the current fiscal year.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.